Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives

Jun Wang; Brent Johnston; Pedro Berraondo

doi:10.3389/fimmu.2022.985326

Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives

Front Immunol. 2022 Jul 26:13:985326. doi: 10.3389/fimmu.2022.985326. eCollection 2022.

Authors

Jun Wang^{1

2

3

4}, Brent Johnston^{1

3}, Pedro Berraondo^{5

6

7}

Affiliations

¹ Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
² Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
³ Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
⁴ Canadian Center for Vaccinology, Halifax, NS, Canada.
⁵ Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
⁶ Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
⁷ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

No abstract available

Keywords: C-C chemokine receptor type 2, chemokine (C-X-C motif) ligand 13; IFN-α; cardiotrophin-like cytokine factor 1; interleukin 34; interleukin-13 receptor subunit alpha-2; transforming growth factor beta; tumor necrosis factor.

Publication types

Editorial

MeSH terms

Cytokines*
Immunotherapy
Receptors, Cytokine*

Substances

Cytokines
Receptors, Cytokine